Given that VEGF supplementation may have the risk of exacerbating diabetic retinopathy and inducing tumors, the study confirmed that there was no progression of diabetic retinopathy and no neoplastic disease after a year of follow-up, which preliminarily suggesting that local VEGF supplementation does not alter systemic angiogenesis status. The gene discussed is VEGFA; the disease is diabetic retinopathy.